In conclusion, BRAFV600E is a common kinase activating alteration in human cancer and in CNS with high prevalence in pLGG, whereby patients with BRAFV600E altered tumors are routinely, successfully treated with molecular targeted therapy (BRAF inhibition). This evidence concerns the gene BRAF and cancer.